北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 内分泌内科  > 期刊论文
学科主题: 临床医学
题名:
Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes
作者: Shi, YF; Pan, CY; Hill, J; Gao, Y
关键词: cardiovascular risk factors ; Chinese ; newly diagnosed Type 2 diabetes ; obesity ; orlistat
刊名: DIABETIC MEDICINE
发表日期: 2005-12-01
DOI: 10.1111/j.1464-5491.2005.01723.x
卷: 22, 期:12, 页:1737-1743
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Endocrinology & Metabolism
研究领域[WOS]: Endocrinology & Metabolism
关键词[WOS]: MODEST WEIGHT-LOSS ; RANDOMIZED CONTROLLED-TRIAL ; CARDIOVASCULAR RISK-FACTORS ; LONG-TERM ; CLINICAL-EFFICACY ; BODY-WEIGHT ; DISEASE ; MELLITUS ; METFORMIN ; HEALTH
英文摘要:

Aims Orlistat promotes weight loss in overweight and obese patients with Type 2 diabetes receiving hypoglycaemic treatment, but has not been investigated in patients with newly diagnosed and previously untreated Type 2 diabetes. We evaluated the efficacy of 24 weeks′ treatment with orlistat, combined with a mildly reduced-calorie diet, on weight loss and glycaemic control in overweight and obese patients with newly diagnosed and previously untreated Type 2 diabetes.

Methods A total of 249 Chinese patients (body mass index 25-40 kg/m(2)) with recently diagnosed Type 2 diabetes were randomized to placebo (n = 124) or orlistat 120 mg (n = 125) three times daily; all patients followed a mildly reduced-calorie diet. Patients had HbA(1c) 6.5-8.5% (mean 7.3%) and had never received any glucose-lowering medication.

Results Orlistat-treated patients achieved significantly greater weight loss at the study end than placebo-treated patients (-5.4 vs. -2.4 kg; P < 0.0001). More orlistat than placebo patients lost >= 5% (60.5 vs. 26.8%; P < 0.0001) and >= 10% of their body weight (20.2 vs. 4.9%; P = 0.0002). A significantly greater decrease in HbA(1c) from baseline was obtained with orlistat than placebo (-1.0 vs. -0.6%; P = 0.0008). Orlistat-treated patients achieved a significantly greater decrease in fasting plasma glucose (-1.3 vs. -0.5 mmol/l; P = 0.0003) and in the 2-h oral glucose tolerance test (-4.1 vs. -1.4 mmol/l; P < 0.0001) than placebo recipients. Also, more orlistat- than placebo-treated patients improved from diabetic status to normal or impaired glucose tolerance (44.3 vs. 32.5%; P = 0.0763) after 24 weeks. Orlistat also produced improvements in lipid profiles and waist circumference.

Conclusions In combination with a mildly reduced-calorie diet, orlistat significantly reduces body weight, and improves glycaemic control and several cardiovascular risk factors in overweight and obese Chinese patients with newly diagnosed Type 2 diabetes.

语种: 英语
WOS记录号: WOS:000233714800018
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/54533
Appears in Collections:北京大学第一临床医学院_内分泌内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Roche Prod Pty Ltd, Dee Why, NSW, Australia
2.Beijing 301 Hosp, Dept Endocrinol, Beijing, Peoples R China
3.Beijing Union Med Coll Hosp, Dept Endocrinol, Beijing 100730, Peoples R China
4.Peking Univ, Hosp 1, Dept Endocrinol, Beijing 100871, Peoples R China

Recommended Citation:
Shi, YF,Pan, CY,Hill, J,et al. Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes[J]. DIABETIC MEDICINE,2005,22(12):1737-1743.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Shi, YF]'s Articles
[Pan, CY]'s Articles
[Hill, J]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Shi, YF]‘s Articles
[Pan, CY]‘s Articles
[Hill, J]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace